Abstract:
INTRODUCTION:Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week ribavirin pre-treatment could increase either adherence or antiviral effect of a 48-week combination therapy. METHODS:Ribavirin pre-treatment (8 weeks) was started with 600 mg daily and increased to 10.4 mg/kg/day. After pre-treatment, 1.5 μg/kg/week pegylated interferon-α2b was added for 48 additional weeks of combination therapy. Blood count, liver function tests and plasma HCV-RNA were examined monthly. Ribavirin plasma concentrations were determined by HPLC. RESULTS:Thirteen patients (mean age 53±2 years, 11 males) were treated: eight were HCV genotype 1/4; five were genotype 2/3. The median baseline HCV RNA level was 6.5 log(10) (range 5.84-7.42 log(10)). During ribavirin pre-treatment the median HCV RNA levels decreased significantly (5.7 log(10) ; P=0.023). During combination therapy 6/13 (46%) patients exhibited a rapid virological response (RVR) and 10/13 (77%) patients a complete early virological response, two were non-responders. A decline of 0.5 log(10) HCV RNA during pre-treatment predicted RVR. SVR occurred in six patients (46%): four were genotype 2/3. Stable ribavirin dose reduction was required in only two patients (15%) in whom transient interferon reduction was also required. CONCLUSION:This proof-of-concept study indicates that ribavirin pre-treatment increased the tolerability of the antiviral treatment, and improved its efficacy in liver transplant patients. Moreover, the degree of HCV RNA decline during pre-treatment allowed one to predict on-treatment response.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Merli M,Giannelli V,Gentili F,Giusto M,Simmaco M,Lionetto L,Corradini SG,Biliotti E,Attili AF,Rossi M,Taliani Gdoi
10.3851/IMP1834subject
Has Abstractpub_date
2011-01-01 00:00:00pages
879-85issue
6eissn
1359-6535issn
2040-2058journal_volume
16pub_type
杂志文章abstract:BACKGROUND:Poor adherence to antiretroviral therapy contributes to pharmacokinetic variability and is the major determinant of virological failure. However, measuring treatment adherence is difficult, especially in children. We investigated the relationship between plasma lopinavir concentrations, pretreatment characte...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2749
更新日期:2014-01-01 00:00:00
abstract:BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,多中心研究
doi:10.3851/IMP1532
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:Potential drug-drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age and comorbidities. We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability. METH...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1540
更新日期:2010-01-01 00:00:00
abstract::Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2222
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2008-01-01 00:00:00
abstract::The effectiveness of current antiretroviral therapies has led to more patients receiving long-term therapy, and increasing numbers of older patients. The complex interactions between HIV infection, ageing, comorbid conditions and drug-related toxicities, and their combined effects on patient health and quality of life...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1470
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1558
更新日期:2010-01-01 00:00:00
abstract::The study was carried out to evaluate the therapeutic effects of zanamivir, a highly selective, potent and specific inhibitor of influenza A and B virus neuraminidases, in adult patients with acute influenza-like illness. Patients who presented within 36 h of the onset of influenza-like symptoms were randomly assigned...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1999-01-01 00:00:00
abstract:BACKGROUND:In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complica...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP1858
更新日期:2011-01-01 00:00:00
abstract::Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:1997-12-01 00:00:00
abstract::HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP1495
更新日期:2010-01-01 00:00:00
abstract:OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2094
更新日期:2012-01-01 00:00:00
abstract::Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP3245
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:HIV-1 shedding in genital secretions is associated with HIV transmission risk. Limited data exist on the effect of second-line lopinavir/ritonavir monotherapy (mLPV/r) on genital secretion of HIV RNA. METHODS:We measured HIV-1 in genital secretions of HIV-infected adults at time of failure from non-nucleosi...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章
doi:10.3851/IMP2737
更新日期:2014-01-01 00:00:00
abstract::We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reachi...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:1996-08-01 00:00:00
abstract:BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3028
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Hepatitis delta virus (HDV) infection therapy is unclear. This systematic analysis aimed to clarify the evidence on the efficacy of interferon (IFN)-α-based therapy in HDV. METHODS:We performed a systematic search on electronic databases including MEDLINE (1970 to January 2011), Web of Science, The Cochrane...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2306
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2013
更新日期:2012-01-01 00:00:00
abstract::The use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of HIV infection is clearly linked to the development of subcutaneous fat atrophy. Until recently, however, in vitro studies of adipocytes have shown no or only modest and inconsistent effects of these agents on adipocyte biology. This is...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:This study aimed to test the hypothesis that the paediatric fixed-dose combination granule for reconstitution (comprising lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml) as a test product is bioequivalent to the coadministered single entities of the referenced products. Fixed-dose combination anti-ret...
journal_title:Antiviral therapy
pub_type: 杂志文章,随机对照试验,评审
doi:10.3851/imp2310
更新日期:2013-01-01 00:00:00
abstract:BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.3851/IMP3202
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Anaemia has been linked with mortality in HIV infection. The mechanism of anaemia in the era of contemporary antiretroviral therapy is not understood. The aim of this study was to describe the association between anaemia and markers of immune activation and inflammation in a cohort of HIV-infected adults on ...
journal_title:Antiviral therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3851/IMP2940
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:There is a paucity of data on the long-term efficacy of combination lamivudine and adefovir therapy in patients with lamivudine-resistant chronic hepatitis B. METHODS:We determined the cumulative virological, serological and biochemical outcomes of 165 lamivudine-resistant chronic hepatitis B patients on la...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP2335
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:10.3851/IMP3160
更新日期:2017-01-01 00:00:00
abstract::The hepatitis C virus (HCV) NS3 protein contains a serine proteinase domain implicated in the maturation of the viral polyprotein. NS3 forms a stable heterodimer with NS4A, a viral membrane protein that acts as an activator of the NS3 proteinase. The three-dimensional structure of the NS3 proteinase complexed with an ...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:1998-01-01 00:00:00
abstract::Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:10.3851/IMP2425
更新日期:2012-01-01 00:00:00
abstract::Zidovudine treatment of human immunodeficiency virus (HIV) infection induces drug-resistant viral strains harbouring specific amino acid substitutions in the reverse transcriptase (RT). To investigate whether this phenomenon could be observed in the case of human T lymphotropic virus type I (HTLV-I) infection, we anal...
journal_title:Antiviral therapy
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...
journal_title:Antiviral therapy
pub_type: 杂志文章,评审
doi:
更新日期:2000-06-01 00:00:00
abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...
journal_title:Antiviral therapy
pub_type: 杂志文章,多中心研究
doi:
更新日期:2007-01-01 00:00:00